Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
Business Wire•13/10/2026•08:00 ET
0
Key Highlights
- ➤Charles River collaborates with Magellan on stem-cell therapy development and commercialization.
- ➤Magellan completed Phase I/II Zelestrocel trials for osteoarthritis and plans pivotal Phase III.
- ➤Charles River will provide cGMP NGS viral-safety testing for Zelestrocel development.
- ➤Magellan secured TGA GMP certification for its Melbourne cell-therapy manufacturing facility.
- ➤Charles River acquired Pathoquest to enhance sequencing-based biopharmaceutical quality-control testing.
Expert Statements
Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River
“Working with organizations at the forefront of innovation allows us to expand our GMP testing capabilities and help accelerate the delivery of safe, compliant therapies to patients”
Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River
“We are excited to support Magellan as they work towards advancing Zelestrocel from the clinic to potential commercialization.”
Julien Freitag, CEO, Magellan Stem Cells
“As we prepare for the next stage of Zelestrocel's development, having access to advanced testing technologies and collaborating with experienced partners is critical to our success,”
Nick Bliesner, COO, Magellan Stem Cells
“Charles River's GMP NGS capabilities provide an innovative approach to viral safety testing that supports both product quality and regulatory readiness. This collaboration strengthens our ability to advance Zelestrocel toward commercialization with confidence.”
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
Collaboration leverages next-generation sequencing (NGS) services to advance development and commercialization of an off-the-shelf therapy for osteoarthritis and future programs
Get started
Create a free account to read the full story.